• Home
  • News
  • Outsourcing Pharma Discusses FDA Guidelines for ADME Programs, Growth Plans with Thierry Van Nieuwenhove Ahead of CPHI Worldwide 2024
Articles & Publications , Thierry Van Nieuwenhove

Outsourcing Pharma Discusses FDA Guidelines for ADME Programs, Growth Plans with Thierry Van Nieuwenhove Ahead of CPHI Worldwide 2024

Thierry Van Nieuwenhove
By: Thierry Van Nieuwenhove
Hexagons on blue gradient background with Quotient Sciences logo

In this article by Outsourcing Pharma,  Quotient Sciences CEO Thierry Van Nieuwenhove shared insights on how the company is adapting to new FDA regulations.

Thierry also discusses how the company is expanding its Translational Pharmaceutics® platforms into new therapeutic areas like mRNA.

Continue reading the full article on Outsourcing Pharma.

Meet the author: Thierry Van Nieuwenhove

Latest news from Quotient Sciences

More News
Articles & Publications, News & Announcements, Matt Paterson First-in-human is not just about safety By: Matt Paterson
Read More
News & Announcements, Articles & Publications, Philadelphia, PA, Marlene Leuenberger Marlene Leuenberger featured in CPHI Online's "A Day in the Life of a Vice President and General Manager" By: Marlene Leuenberger
Read More
Articles & Publications, News & Announcements, Dr. Andrew Lewis Dr. Andrew Lewis Contributes to The Medicine Maker's "How Speed, Scale, and Science Can Personalize the Pandemic Response" By: Dr. Andy Lewis
Read More
More News
Let's Talk
Your breakthrough therapy deserves momentum, and every day matters. Start a conversation with us today.
Contact Us Therapy Areas